ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2025
Coaxial electrospun fibers for control release of vancomycin and diclofenac in osteomyelitis management.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteomyelitis (OM) is a serious bacterial bone infection and can be life-threatening if not treated promptly. A promising approach to manage OM involves using drug-loaded fibrous implants or scaffolds containing antibiotics, analgesics, or anti-osteoporosis medications to combat infection, reduce pain and promote bone healing, respectively. In this study, a coaxial electrospinning technology was employed to fabricate drug-loaded fibers encapsulating vancomycin hydrochloride (VAN), an antibiotic, and diclofenac sodium (DIC), an analgesic to prevent infection and alleviate post-surgical pain. The fibers were characterized using scanning electron microscopy (SEM) which indicated that the drug-loaded (DL) coaxial fibers had smooth surfaces and lacked beads and pores. The drug loading of the DL coaxial fibers was estimated by high-performance liquid chromatography (HPLC), and the results were calculated as 75 ± 4 µg/mL for VAN and 82 ± 3 µg/mL for DIC. The drug release was also measured by HPLC, which showed a rapid initial release, i.e., 59% for VAN and 75% for DIC within the first day, followed by a sustained slow release reaching approximately 92% and 79%, respectively after 264 h. The antimicrobial assay zone of inhibition confirmed the antibacterial activity of the DL fibers against Staphylococcus aureus. The cell viability assessments on the drugs alone against human dermal fibroblasts (HFF-1) demonstrated that the VAN and DIC combination is safe at concentrations up to 250 µg/mL but required careful dosing due to time-dependent cytotoxicity. Overall, the study highlights the potential use of VAN and DIC-loaded coaxial electrospun fibers as a localized drug delivery system for OM treatment, offering controlled drug release, effective antibacterial action, and biocompatibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.